

**Supporting Information:**

**Controlled delivery of a protein tyrosine  
phosphatase inhibitor, SHP099, using  
cyclodextrin-mediated host-guest interactions in  
polyelectrolyte multilayer films for cancer therapy**

Soobin Wang,<sup>†</sup> Alessia Battigelli,<sup>†,‡</sup> Dahlia Alkekha,<sup>†,‡</sup> Alexis Fairman,<sup>†,‡</sup>  
Valentin Antoci,<sup>¶</sup> Wentian Yang,<sup>¶</sup> Douglas Moore,<sup>¶</sup> and Anita Shukla<sup>\*,†,‡,§,||</sup>

<sup>†</sup>*School of Engineering, Brown University, Providence, RI 02912*

<sup>‡</sup>*Center for Biomedical Engineering, Brown University, Providence, RI 02912*

<sup>¶</sup>*Department of Orthopaedics, Warren Alpert Medical School, Brown University and Rhode  
Island Hospital, Providence, RI 02912*

<sup>§</sup>*Institute for Molecular and Nanoscale Innovation, Brown University, Providence, RI  
02912*

<sup>||</sup>*corresponding author*

E-mail: anita\_shukla@brown.edu

# 1 2D NOESY NMR of Controls




Figure S1: 2D NOESY NMR of (a) SHP099 and (b)  $P\beta$ CD dissolved in  $D_2O$  (600 MHz).

## 2 SHP099 *in vitro* cytocompatibility

Cytocompatibility of SHP099 was assessed for NIH 3T3 murine fibroblasts. NIH 3T3 cells were cultured in DMEM (containing 4 mM l-glutamine, 4500 mg/L glucose, 1 mM sodium pyruvate, and 1500 mg/L sodium bicarbonate) supplemented with 10% v/v calf bovine serum and 1% v/v penicillin–streptomycin at 37°C and 5% CO<sub>2</sub>. Cells were seeded in 96-well plates at a seeding density of approximately 2500 cells/cm<sup>2</sup>. After 24 h, cells were treated with increasing concentration of SHP099 (from 1.25 to 50 μM), similarly to the clonogenic assays. Cell viability was measured using CCK8 following the vendor protocol. Briefly, after 24 h of SHP099 incubation with the cells, the solutions were removed and 100 μL of CCK8 reagent was added. After 2 h of incubation at 37°C, absorbance at 450 nm was measured using a BioTek<sup>®</sup> Cytation 3 plate reader. Positive controls of cells grown in DMEM and negative controls lacking cells were included. Normalized cell viability was calculated using Eq. (1).

$$\text{Normalized cell viability \%} = \frac{\text{sample abs} - \text{negative control abs}}{\text{positive control abs} - \text{negative control abs}} \times 100 \quad (1)$$




Figure S2: NIH 3T3 fibroblast viability in media incubated with increasing concentration of SHP099 for 14 days to assess biocompatibility of the drug on non cancer cells. Viability and statistical significance are shown relative to the untreated cell control. Results are reported as means  $\pm$  standard deviations. Statistical significance was examined using one-way ANOVA and Tukey's post-hoc analysis compared to untreated controls,  $n \geq 3$ ,  $\alpha=0.05$ , \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\*\* $p < 0.0001$ ;  $n=3$ .